Research
Hormonal
Inhibition of the p38 MAPK pathway in white adipose tissue promotes the reprogramming of white adipocytes to beige adipocytes, leading to resistance against diet-induced obesity.
Research suggests that targeting specific signaling pathways like p38 MAPK could potentially help convert energy-storing white fat into energy-burning beige fat, offering a potential future therapeutic strategy for obesity.
ModerateSupportsMEDIUM confidence
In white adipocytes, inactivation of p38α leads to increased reprogramming from white to beige adipocytes and resistance to diet-induced obesity.
Why this rating
Based on mouse models (liver specific p38α knockout mice) and mechanistic studies.
Source
The signaling pathways in obesity‐related complications
Preethi Chandrasekaran et al. · Journal of Cell Communication and Signaling · 2024
DOI 10.1002/ccs3.12039
narrative_reviewCited 29×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity exacerbates cardiovascular disease (CVD) risk and mortality through structural and metabolic mechanisms, including visceral fat deposition, pro-inflammatory cytokine release (TNF-α, IL-1, IL-6), and lipotoxicity from free fatty acids and ceramides.Good
- Activation of the AMPK pathway in adipocytes inhibits adipogenesis, enhances insulin sensitivity, promotes thermogenesis, and leads to weight loss, whereas activation in the central nervous system results in weight gain and increased appetite.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →